With the space continuing its upward trajectory with more compounds moving through the clinic, it’s an exciting time to be in the targeted radiopharmaceuticals space!

The 2^nd Annual Targeted Radiopharmaceuticals Summit US returned as the only industry-led meeting dedicated to accelerating TRP programs by discovering more-specific tumur-associated targets, increasing access and low-cost availability of radionuclides, and maximizing preclinical and clinical search of combination therapy with agents and treatment modalities.

We united 100+ key stakeholders across the space from large pharma, biotech, academia, physicians, nuclear physicists, cyclotron providers, manufacturers, linker developers, TRP-experienced CROs & many more, to bring the targeted radiotherapies to the forefront of cancer treatment.

Take this unique opportunity to connect with all the key players in the targeted radiopharmaceuticals space as they learn the ins-and-outs of the progress, gain a deep and holistic insight of the current state-of-play in the US TRP landscape, and challenges the leading experts in the space are experiencing.